Immunotherapy of Hepatocellular Carcinoma Using Chimeric Antigen Receptors and Bispecific Antibodies

Overview

Journal Cancer Lett

Specialty Oncology

Date 2017 Apr 22

PMID 28428075

Citations 25

Authors

Sayed Shahabuddin Hoseini

Nai-Kong V Cheung

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide with an overall survival rate of less than 15% in developed countries. Despite attempts at new therapeutic strategies, the majority of patients succumb to this cancer. Buttressed by the highly successful clinical impact in melanoma, immunotherapy is gaining momentum as the next treatment modality for many human cancers. Chimeric antigen receptors (CAR) contain the antigen binding moieties of a monoclonal antibody and the co-stimulatory and signaling domains associated with effector receptor signaling. Bispecific antibodies (BsAb) combine the binding specificities of two different monoclonal antibodies, one activating a receptor on a killer effector cell, while the other engaging a tumor-associated antigen to initiate tumor cytotoxicity. In this review, we survey the HCC targets for which CARs and bispecific antibodies have been generated. The pros and cons of these targets for T-cell and Natural Killer cell based immunotherapy will be discussed.

Citing Articles

Racial/Ethnic Disparities and Immunotherapeutic Advances in the Treatment of Hepatocellular Carcinoma.

Garcia A, Mathew S Cancers (Basel). 2024; 16(13).

PMID: 39001508 PMC: 11240753. DOI: 10.3390/cancers16132446.

Insights in Molecular Therapies for Hepatocellular Carcinoma.

Heumann P, Albert A, Gulow K, Tumen D, Muller M, Kandulski A Cancers (Basel). 2024; 16(10).

PMID: 38791911 PMC: 11120383. DOI: 10.3390/cancers16101831.

Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.

Shen K, Zhu Y, Xie S, Qin L J Hematol Oncol. 2024; 17(1):25.

PMID: 38679698 PMC: 11057182. DOI: 10.1186/s13045-024-01549-2.

Treatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future.

Wei H, Dong C, Li X J Clin Transl Hepatol. 2024; 12(4):389-405.

PMID: 38638377 PMC: 11022065. DOI: 10.14218/JCTH.2023.00462.

Bispecific antibodies revolutionizing breast cancer treatment: a comprehensive overview.

Lan H, Chen M, Yao S, Chen J, Jin K Front Immunol. 2023; 14:1266450.

PMID: 38111570 PMC: 10725925. DOI: 10.3389/fimmu.2023.1266450.

References

Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim H . CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest. 2010; 120(9):3326-39. PMC: 2929722. DOI: 10.1172/JCI42550. View

Sun T, Gao Q, Qiu S, Zhou J, Wang X, Yi Y . B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence. Cancer Immunol Immunother. 2012; 61(11):2171-82. PMC: 11029627. DOI: 10.1007/s00262-012-1278-5. View

Chen Y, Huang Y, Reiberger T, Duyverman A, Huang P, Samuel R . Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology. 2013; 59(4):1435-47. PMC: 3966948. DOI: 10.1002/hep.26790. View

Xiao X, Lao X, Chen M, Liu R, Wei Y, Ouyang F . PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression. Cancer Discov. 2016; 6(5):546-59. DOI: 10.1158/2159-8290.CD-15-1408. View

Hsu H, Cheng W, Lai P . Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res. 1997; 57(22):5179-84. View

Tarocchi M, Polvani S, Marroncini G, Galli A . Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. World J Gastroenterol. 2014; 20(33):11630-40. PMC: 4155355. DOI: 10.3748/wjg.v20.i33.11630. View

Xu X, Liu R, Zhang X, Huang L, Chen F, Fei Q . DLK1 as a potential target against cancer stem/progenitor cells of hepatocellular carcinoma. Mol Cancer Ther. 2012; 11(3):629-38. DOI: 10.1158/1535-7163.MCT-11-0531. View

Saijyo S, Kudo T, Katayose Y, Saeki H, Chiba N, Suzuki M . A new in vitro model of specific targeting therapy of cancer: retargeting of PWM-LAK cells with bispecific antibodies greatly enhances cytotoxicity to hepatocellular carcinoma. Tohoku J Exp Med. 1996; 178(2):113-27. DOI: 10.1620/tjem.178.113. View

Yamashita T, Forgues M, Wang W, Kim J, Ye Q, Jia H . EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008; 68(5):1451-61. DOI: 10.1158/0008-5472.CAN-07-6013. View

10.

Chuang W, Liu H, Chang W . Natural killer cell activity in patients with hepatocellular carcinoma relative to early development and tumor invasion. Cancer. 1990; 65(4):926-30. DOI: 10.1002/1097-0142(19900215)65:4<926::aid-cncr2820650418>3.0.co;2-u. View

11.

Bandopadhyay M, Bulbule A, Butti R, Chakraborty G, Ghorpade P, Ghosh P . Osteopontin as a therapeutic target for cancer. Expert Opin Ther Targets. 2014; 18(8):883-95. DOI: 10.1517/14728222.2014.925447. View

12.

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

13.

Petsch S, Gires O, Ruttinger D, Denzel S, Lippold S, Baeuerle P . Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110. MAbs. 2010; 3(1):31-7. PMC: 3038009. DOI: 10.4161/mabs.3.1.14193. View

14.

Ang W, Li Z, Chi Z, Du S, Chen C, Tay J . Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis. Oncotarget. 2017; 8(8):13545-13559. PMC: 5355119. DOI: 10.18632/oncotarget.14592. View

15.

Chen Q, Sun P, Prigione I, Xie H, Ferrini S . Targeting of "T" lymphocytes against human hepatoma cells by a bispecific monoclonal antibody: role of different lymphocyte subsets. Tumori. 1992; 78(2):79-86. DOI: 10.1177/030089169207800204. View

16.

Gao B, Jeong W, Tian Z . Liver: An organ with predominant innate immunity. Hepatology. 2008; 47(2):729-36. DOI: 10.1002/hep.22034. View

17.

Seimetz D . Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab). J Cancer. 2011; 2:309-16. PMC: 3119393. DOI: 10.7150/jca.2.309. View

18.

Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J . Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer. 2009; 126(9):2067-78. DOI: 10.1002/ijc.24868. View

19.

Beatty G, Haas A, Maus M, Torigian D, Soulen M, Plesa G . Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014; 2(2):112-20. PMC: 3932715. DOI: 10.1158/2326-6066.CIR-13-0170. View

20.

Ferrara N . Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004; 25(4):581-611. DOI: 10.1210/er.2003-0027. View